Pneumococcal Infections | Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
Pneumococcal Infections research study
What is the primary objective of this study?
This is a randomized, double-blind, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive GEN-004 with adjuvant or placebo. Each subject will receive up to 3 doses at 4 week intervals. Following the third dose, subjects will be inoculated intranasally with S. pneumoniae serotype 6B. Nasal washes to identify S. pneumoniae colonization will be obtained pre-inoculation, and then 2, 7 and 14 days after inoculation. Subjects will also be monitored for safety and tolerability throughout the dosing period, and then for 12 months after their last dose. The purpose of this study is to evaluate the effectiveness of GEN-004 in reducing colonization rates and magnitude of colonization following the S. pneumoniae challenge.
Who is eligible to participate?
Inclusion Criteria: - Males and non-pregnant females, ages 18 to 55 years inclusive. - Willing and able to provide written informed consent. - Fluent English speakers only (for safety reasons) - Willing to perform and comply with all study procedures including attending clinic visits as scheduled. Exclusion Criteria: - Prior vaccination with pneumococcal vaccine. - History of invasive pneumococcal disease (i.e., sepsis, meningitis or pneumonia with bacteremia). - Close contact with at risk individuals (young children [under 5years], immunosuppressed adults, elderly, chronic ill health). - Current smoker or significant smoking history (>10 pack years). - Pregnant or breast-feeding woman. - Women of child-bearing potential (WOCBP) who are deemed not to have sufficient, effective birth control in place for 1 month prior to vaccination and 1 month after the final vaccination. - Allergy to penicillin or amoxicillin. - Any screening laboratory value > Grade 1 - Positive serologic test for HIV-1 or hepatitis C infection; positive hepatitis B surface antigen (HBsAg). - Asthma (on regular medication) or other respiratory disease. - Immunocompromised individuals, including those receiving corticosteroids or other immunosuppressive agents. - Presence or history of auto-immune disease (refer to Appendix 4) regardless of current treatment. - No antibiotic treatment within 1 week of inoculation - Previous involvement in EHPC study inoculated with pneumococcal bacteria - In any other clinical trial unless in observational stage or follow-up - Diabetes, type 1 or type 2. - Other active, uncontrolled co-morbidities that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements. NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be enrolled if there have been no changes to their medication within 60 days prior to first dose of Study Drug.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Biological:GEN-004 with Aluminum Hydroxide AdjuvantGEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection. GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens: GB104: ABC transporter, substrate-binding protein GB144: Maltose/maltodextrin binding protein, ABC transporter GB152: Hypothetical protein GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen). Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL.
Biological:PlaceboPlacebo: normal saline, 0.5 mL per dose, IM.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
GEN-004 with Aluminum Hydroxide
Start Date: September 2014
Completed Date: April 2016
Phase: Phase 2
Primary Outcome: Efficacy of GEN-004 with aluminum hydroxide in healthy adult subjects to reduce nasopharyngeal colonization following intranasal inoculation with S. pneumoniae serotype 6 as measured by proportion of colonized subjects
Secondary Outcome: Safety and tolerability of GEN-004 with aluminum hydroxide
Study sponsors, principal investigator, and references
Principal Investigator: Richard Fitzgerald, MD
Lead Sponsor: Genocea Biosciences, Inc.